TritonPoint Wealth’s Biogen BIIB Stock Holding History

TritonPoint Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,060	Closed	-$246K	–	332
2024 Q2	$246K	Sell	1,060 -1,261	-54%	-$274K	0.02%	280
2024 Q1	$521K	Buy	2,321 +298	+15%	+$69.8K	0.05%	201
2023 Q4	$523K	Buy	+2,023	New	+$497K	0.05%	209

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TritonPoint Wealth's BIIB Position: Q3 2024 in Review

TritonPoint Wealth sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,060 shares — an estimated $246K sold.

TritonPoint Wealth first reported a position in BIIB in Q4 2023 and held it in 3 quarters. The position peaked at $523K in Q4 2023. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

TritonPoint Wealth reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
TritonPoint Wealth sold 1,060 Biogen shares in Q3 2024, an estimated $246K.
TritonPoint Wealth first reported a position in Biogen in Q4 2023 and held it in 3 quarters.
TritonPoint Wealth's Biogen position peaked at $523K in Q4 2023.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on TritonPoint Wealth's 13F filing for Q3 2024, filed 28 Oct 2024.